recent
year
increas
develop
vaccin
technolog
ideal
vaccin
alreadi
found
gener
term
criteria
vaccin
must
satisfi
must
capabl
elicit
appropri
immun
respons
safe
stabl
reproduc
issu
cost
number
administr
immun
rout
may
also
taken
account
tradit
vaccin
develop
use
live
attenu
organ
calmetteguerin
measl
mump
rubella
varicella
kill
inactiv
whole
organ
eg
influenza
inactiv
toxin
includ
diphtheria
tetanu
live
vaccin
advantag
produc
humor
cellular
immun
respons
often
requir
one
boost
howev
vaccin
environment
labil
requir
refriger
make
difficult
deliveri
therapeut
agent
especi
develop
countri
furthermor
use
attenu
pathogen
revert
activ
form
danger
particularli
acut
immunecompromis
individu
kill
inactiv
organ
gener
weaker
immun
respons
typic
requir
multipl
dose
henc
type
vaccin
gener
requir
addit
adjuv
effect
disadvantag
led
develop
subunit
vaccin
includ
synthet
peptid
antigen
consist
specif
part
whole
pathogen
demonstr
stimul
immun
respons
vaccin
attract
revert
virul
form
produc
bulk
safe
reproduc
howev
subunit
vaccin
rel
low
immunogen
make
necessari
use
adjuv
andor
vaccin
deliveri
system
besid
proteinbas
vaccin
may
degrad
proteas
activ
limit
bioavail
sinc
often
cross
biolog
membran
find
optim
combin
given
synthet
peptid
adjuv
open
unlimit
clinic
potenti
vaccin
adequ
epitop
identifi
certain
diseas
antigen
could
synthes
demand
reason
success
adjuv
need
safe
well
toler
simpli
produc
inexpens
compound
biodegrad
compat
mani
differ
antigen
capabl
function
deliveri
system
immun
potenti
therefor
licens
new
newli
formul
vaccin
nonclin
clinic
data
regard
safeti
efficaci
requir
next
pharmaceut
qualiti
data
data
need
activ
ingredi
well
adjuv
deliveri
system
combin
final
product
regard
one
guidelin
specif
dedic
peptid
guidanc
industri
submiss
chemistri
manufactur
control
inform
synthet
peptid
substanc
publish
stipul
lot
releas
specif
suffici
ensur
ident
puriti
strength
peptid
demonstr
lottolot
consist
need
elicit
humor
cellular
immun
respons
limit
efficaci
certain
pathogen
malaria
hiv
activ
cytolyt
immun
respons
ctl
need
case
intracellular
pathogen
tumor
mediat
cell
cell
natur
killer
cell
dendrit
cell
dc
sever
innat
featur
make
ideal
target
vaccin
purpos
captur
antigen
enter
bodi
move
cell
area
lymphoid
organ
find
right
clone
start
immun
respons
peripher
tissu
dc
found
immatur
stage
special
captur
foreign
antigen
respons
microb
dc
undergo
process
matur
antigenpres
cell
apc
meanwhil
migrat
peripheri
drain
lymph
node
present
antigen
lymphocyt
dc
present
peptid
cell
context
major
histocompat
complex
mhc
class
ii
molecul
also
glycolipid
glycopeptid
cell
nkt
cell
well
polypeptid
b
cell
order
achiev
ctl
respons
cytolyt
cell
must
specif
recogn
pathogenderiv
antigen
present
mhc
class
complex
upon
antigen
recognit
immun
cell
releas
cytolyt
agent
directli
destroy
infect
cell
induc
inflammatori
reaction
facilit
innat
immun
clearanc
develop
humor
respons
order
gener
cell
immun
respons
crosspresent
occur
exogen
antigen
present
mhc
molecul
order
promot
strong
cytolyt
inflammatori
bia
proteinbas
vaccin
develop
cytolyt
respons
readili
process
mhc
class
ii
molecul
trigger
humor
antibodydepend
immun
respons
develop
ctl
respons
antigen
escap
endosom
compart
cytosol
endoplasm
reticular
space
crosspresent
occur
micro
nanoparticlebas
vaccin
deliveri
system
function
antigen
carrier
particul
natur
inher
abil
facilit
antigen
crosspresent
sinc
resembl
pathogen
particul
structur
look
like
biolog
situat
particl
per
se
passiv
direct
apc
increas
interact
cell
antigen
due
particl
slow
degrad
apart
depot
effect
particul
adjuv
directli
activ
innat
immun
vivo
work
immunoadjuv
thu
modif
system
directli
target
apc
may
good
approach
improv
efficaci
therefor
micro
nanoparticul
deliveri
system
lead
good
opportun
develop
synthet
peptidebas
vaccin
figur
prepar
micro
nanodevic
key
formul
aspect
chemic
composit
manufactur
process
affect
antigen
load
capac
releas
profil
product
stabil
efficaci
safeti
instanc
differ
size
micro
nanoparticl
may
chang
immun
respons
achiev
smaller
particl
greater
proport
drug
locat
surfac
lead
substanti
loss
payload
lower
maxim
drug
load
smaller
particl
final
may
affect
adjuv
activ
moreov
prepar
process
micro
nanoparticl
lead
stabil
problem
due
exposur
strong
stress
condit
eg
aqueousorgan
interfac
hydrophob
surfac
vigor
shake
reason
peptid
stabil
entrap
formul
evalu
sinc
unlik
develop
univers
encapsul
approach
appropri
everi
peptid
instanc
order
studi
stabil
peptid
encapsul
plga
mp
carcaboso
et
al
analyz
peptid
integr
polyacrylamid
gel
electrophoresi
show
band
indic
partial
degrad
aggreg
protein
nowaday
market
vaccin
compos
synthet
peptid
howev
approv
vaccin
base
micro
nanotechnolog
alum
wide
use
adjuv
human
vaccin
form
particul
aluminium
salt
gener
al
oh
shown
tabl
use
variou
vaccin
combin
vaccin
contain
antigen
diphtheria
tetanu
pertusiss
hepat
b
recombivax
hb
engerix
b
recent
particul
adjuv
licens
human
use
emuls
like
compon
fluad
pandemrix
respect
vaccin
epax
inflex
includ
virosom
latest
approv
system
compos
combin
adjuv
approv
human
use
europ
usa
compris
mpl
monophosphoril
lipid
alum
use
fendrix
combin
viru
like
particl
vlp
use
cervarix
gardasil
paper
summar
micro
nanoparticul
deliveri
system
use
develop
synthet
peptidebas
vaccin
also
discuss
variou
strategi
improv
efficaci
develop
appropri
immun
respons
tabl
aluminium
salt
gener
al
oh
often
call
alum
wide
use
human
year
recent
adjuv
approv
human
use
usa
current
mani
vaccin
contain
alum
recombivax
hb
engerix
b
alum
adjuvanc
associ
enhanc
antibodi
respons
shown
ovaalum
administr
effector
respons
gener
helper
cell
produc
littl
addit
li
et
al
demonstr
alum
enhanc
product
cytokin
inhibit
protein
chemokin
specif
cell
shown
alum
induc
rapid
cell
recruit
inject
site
kool
et
al
demonstr
intraperiton
inject
alum
local
product
chemoatract
like
trigger
well
recruit
neutrophil
eosinophil
monocyt
subsequ
dc
studi
also
reveal
follow
intraperiton
intramuscular
administr
alum
recruit
monocyt
migrat
drain
lymph
node
differenci
inflammatori
dc
capabl
prime
cell
sever
action
mechan
propos
order
explain
alum
adjuvanc
previous
thought
alum
form
depot
antigen
slowli
releas
convert
antigen
particul
form
facilit
phagocytosi
apc
later
shown
alum
induc
inflammatori
respons
recruit
activ
apc
captur
antigen
recent
data
demonstr
alum
target
nodlik
receptor
protein
mediat
activ
releas
lipopolysaccharid
lp
prime
macrophag
interact
cardin
asc
apoptosisassoci
specklik
protein
form
complex
call
inflammasom
turn
mediat
activ
activ
form
figur
howev
vivo
data
demonstr
dispens
adjuv
activ
nevertheless
group
reach
conflict
conclus
eisenbarth
et
al
li
et
al
found
abrog
antibodi
respons
coadminist
antigen
absenc
signal
wherea
kool
et
al
found
partial
inhibit
respons
howev
result
may
explain
fact
differ
alum
formul
use
studi
differ
level
tlr
toll
like
receptor
agonist
use
studi
suggest
could
stimul
though
indirect
mechan
kool
et
al
found
follow
alum
administr
increas
endogen
danger
signal
uric
acid
happen
neutral
uric
acid
uricas
led
inhibit
inflammatori
respons
induc
alum
sever
investig
studi
immun
respons
achiev
combin
synthet
peptid
alum
instanc
phase
clinic
trial
conduct
long
synthet
peptid
plasmodium
falciparum
combin
either
alum
montanid
isa
adjuv
formul
administ
subcutan
peptid
dose
day
although
seriou
advers
event
observ
advers
event
preval
montanid
isa
group
hand
vaccin
gener
antibodi
capac
mediat
growthinhibitori
activ
p
falciparum
vitro
howev
nowaday
alum
adjuv
replac
system
improv
immun
respons
achiev
gener
use
control
combin
adjuv
exampl
raman
et
al
investig
immunomodulatori
effect
two
type
cpg
adjuv
intranas
administ
five
synthet
peptid
antigen
plasmodium
vivax
alum
microparticl
addit
alum
cpg
increas
fourfold
antibodi
titer
trigger
predomin
isotyp
high
titer
one
peptid
signific
inhibitori
effect
parasit
develop
mosquito
peptidespecif
antisera
react
airdri
parasit
antigen
isol
p
vivax
patient
adjuv
compos
emuls
includ
oil
water
ow
water
oil
wo
system
two
formul
approv
human
use
europ
also
anoth
compound
montanid
phase
iii
stage
trial
squalenebas
ow
emuls
licens
influenza
vaccin
fluad
vaccin
safe
demonstr
better
immunogen
nonadjuv
one
even
elderli
childhood
evalu
safeti
data
clinic
trial
involv
reveal
adjuv
subject
lower
risk
nonadjuv
one
undergo
unsolicit
advers
event
hand
adjuv
subject
higher
risk
expect
local
mild
moder
pain
injectionsit
warmth
indur
erythema
system
reaction
myalgia
headach
fatigu
malais
effect
exposur
pregnanc
also
evalu
tsai
et
al
analys
clinic
trial
databas
novarti
vaccin
studi
found
distribut
pregnanc
outcom
normal
abnorm
end
therapeut
abort
similar
subject
expos
compar
non
expos
one
time
pregnanc
specif
earli
pregnanc
although
data
draw
definit
conclus
avail
observ
far
indic
signal
risk
despit
wide
use
mechan
action
well
understood
immunofluoresc
analysi
show
promot
antigen
uptak
dc
intramuscular
inject
suggest
adjuvanc
mediat
depot
effect
studi
compar
adjuv
effect
alum
cpg
character
chang
express
gene
intramuscular
inject
mice
stronger
induc
cytokin
cytokin
receptor
adhes
molecul
involv
leukocyt
migrat
antigen
present
gene
studi
hypothesis
combin
antigen
deliveri
function
strong
immunostimul
activ
moreov
may
also
promot
sustain
antigenpresent
trigger
recruit
monocyt
might
differenti
function
inflammatori
dc
express
high
level
mhc
class
ii
previous
describ
alum
tocopherol
ow
emulsionbas
adjuv
use
pandemrix
influenza
pandem
vaccin
clinic
trial
demonstr
adjuv
vaccin
abl
trigger
immun
respons
compar
obtain
nonadjuv
one
use
fourfold
lower
dose
addit
vaccin
well
toler
solicit
advers
event
transient
mainli
mild
moder
intens
therefor
high
reduct
dose
haemagglutinin
achiev
induc
crossclad
immun
human
prerequisit
effect
prepandem
vaccin
strategi
moreov
recent
clinic
trial
suggest
pandemrix
use
children
month
old
highli
immunogen
overal
reactogen
profil
accept
although
reaction
includ
fever
tend
increas
second
dose
howev
knowledg
studi
publish
combin
use
synthet
peptid
montanid
wo
emulsionbas
adjuv
although
yet
approv
human
use
lot
clinic
trial
undergo
sever
diseas
malaria
melanoma
nonsmal
cell
lung
cancer
studi
carri
laboratori
compar
immun
respons
malari
synthet
peptid
use
montanid
polylactidecoglicolid
plga
microparticl
aluminium
hydroxid
subcutan
administ
montanid
microspher
result
effect
adjuv
reveal
mix
immun
respons
howev
previou
studi
shown
montanid
effect
elicit
antibodi
peptid
peptid
addit
recent
clinic
trial
carri
evalu
safeti
toler
immunogen
mixtur
n
r
c
long
synthet
peptid
deriv
p
vivax
circumsporozoit
protein
formul
two
type
montanid
isa
isa
howev
result
studi
yet
publish
polymer
micro
nanoparticlebas
vaccin
deliveri
system
wide
studi
commonli
use
polym
poli
llacticcoglycol
acid
plga
deriv
figur
due
inher
advantag
system
biodegrad
biocompat
abl
releas
molecul
long
period
time
week
month
eas
administ
via
inject
oral
addit
plga
approv
human
use
sutur
bone
implant
screw
well
implant
sustain
drug
deliveri
apart
plga
polym
also
use
vaccin
purpos
algin
chitin
albumin
sodium
polyacryl
chitosan
poli
acid
well
polym
combin
formul
antigen
either
entrap
adsorb
surfac
particl
deliveri
antigen
slow
continu
puls
trigger
extern
environment
factor
chang
ph
temperatur
ionic
strength
electr
magnet
field
particl
size
size
distribut
import
factor
determin
antigen
releas
rate
total
surfac
area
protein
deliveri
depend
particl
size
regard
particl
size
shown
influenc
type
immun
respons
achiev
fact
nano
microparticl
np
mp
behaviour
vivo
kanchan
panda
show
hbsagload
polylactid
mp
elicit
higher
longlast
antibodi
titer
taken
macrophag
surfac
addit
mp
promot
secret
upregul
mhc
class
ii
molecul
favour
immun
respons
hand
np
nm
effici
phagocyt
macrophag
elicit
lower
antibodi
titer
higher
level
product
upregul
mhc
class
molecul
along
antibodi
isotyp
favour
immun
respons
moreov
manolova
et
al
demonstr
intraderm
administ
smallsiz
polystyren
particl
nm
rapidli
transport
lymph
node
taken
resid
dc
contrast
larg
particl
nm
depend
cellular
transport
skin
dc
despit
differ
clear
type
particl
would
better
particular
case
therefor
particl
size
would
individu
studi
hand
administr
rout
particl
may
influenc
immun
respons
elicit
mohanan
et
al
studi
bia
immun
respons
mice
immunis
differ
rout
subcutan
intraderm
intramuscular
intralymphat
rout
ovalbuminload
liposom
ntrimethylchitosan
np
plga
mp
without
immunerespons
modifi
studi
demonstr
associ
immun
respons
sensit
rout
administr
wherea
respons
associ
respons
rel
insensit
administr
rout
particul
deliveri
system
regard
mechan
action
shown
similarli
alum
plga
microspher
enhanc
secret
dc
addit
trigger
activ
abil
requir
particl
uptak
dc
activ
although
presenc
tlr
agonist
requir
induc
releas
vitro
inject
particl
absenc
tlr
agonist
induc
product
inject
site
indic
endogen
factor
synerg
particl
promot
inflammasom
activ
studi
also
show
enhanc
antigenspecif
antibodi
product
microparticl
independ
need
order
microspher
promot
antigenspecif
product
cell
recruit
activ
cell
howev
studi
show
administr
lpsmodifi
plga
microspher
load
antigen
ovalbumin
preferenti
intern
dc
compar
nonmodifi
particl
addit
particl
elicit
potent
humor
cellular
immun
ovalbumin
wildtyp
macrophag
increas
releas
consist
inflammasom
activ
data
highlight
still
controversi
mechan
action
polymer
micro
nanoparticl
plga
micro
nanospher
use
system
mucos
immun
plgabas
system
abl
phagocytos
dc
even
oral
rout
enhanc
immunostimulatori
capac
lead
upregul
matur
marker
releas
shown
synthet
peptid
peptid
induc
potent
antigenspecif
cytotox
tlymphocyt
respons
encapsul
conjug
surfac
plga
nanoparticl
abl
activ
human
mous
dc
potent
free
peptid
plga
microspher
extens
studi
research
group
differ
synthet
peptid
entrap
microspher
malari
administ
subcutan
intraderm
oral
nasal
rout
mice
microencapsul
induc
superior
immun
respons
one
obtain
administr
peptid
adjuv
alum
compar
respons
obtain
fca
addit
particl
administ
aoutu
monkey
lead
high
antibodi
level
protect
p
falciparum
challeng
knowledg
one
clinic
trial
carri
use
plga
synthet
peptid
phase
studi
evalu
safeti
immunogen
synthet
hiv
peptid
mn
administ
intramuscularli
alum
similar
product
encapsul
plga
microspher
administ
oral
rout
howev
oral
administr
vaccin
trigger
signific
humor
cellular
mucos
immun
respons
liposom
synthet
sphere
compris
phospholipid
bilay
figur
accord
structur
size
liposom
classifi
multilamellar
vesicl
mlv
small
unilamellar
vesicl
suv
intermedi
unilamellar
vesicl
iuv
larg
unilamellar
vesicl
luv
vaccin
deliveri
antigen
encapsul
aqueou
core
integr
lipid
bilay
adsorb
surfac
mechan
action
liposom
well
defin
passiv
target
deriv
particul
natur
tendenc
interact
macrophag
like
import
factor
particularli
nontarget
liposom
among
differ
lipid
avail
cation
one
better
abil
initi
potenti
immun
respons
shown
posit
charg
import
factor
retent
liposom
inject
site
neutral
liposom
shown
limit
abil
mediat
longterm
antigen
present
circul
antigenspecif
cell
induc
arm
immun
system
compar
cation
liposom
neutral
liposom
howev
induc
product
level
compar
cation
liposom
indic
induc
weak
respons
liposom
composit
may
also
affect
type
immun
respons
achiev
inclus
fusogen
lipid
formul
ie
easili
fuse
lipid
membran
dope
lead
superior
respons
ova
indic
direct
toward
respons
coupl
antigen
liposom
surfac
lead
ctl
immun
respons
ctl
epitop
compos
synthet
peptid
deriv
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
coupl
surfac
liposom
effect
peptidespecif
ctl
induct
mice
one
peptid
also
abl
clearanc
vaccinia
viru
expres
epitop
sarscov
challeng
suggest
surfacelink
liposom
peptid
might
offer
effect
ctlbase
vaccin
diseas
hand
demonstr
even
small
amount
antigen
entrap
liposom
induc
antibodi
via
toward
pronounc
antigen
entrap
liposom
also
induc
antigenspecif
antitumor
immun
liposom
graft
synthet
peptid
deriv
dc
matur
signal
highmobl
group
box
abl
target
macrophag
dc
vitro
vivo
coupl
liposom
tumor
deriv
plasma
membran
vesicl
inhibit
tumor
growth
metastasi
tumor
challeng
mice
viru
like
particl
vlp
obtain
viral
structur
protein
produc
recombin
express
system
even
cellfre
system
recombin
viral
structur
protein
sever
virus
spontan
assembl
vlp
absenc
viral
genet
materi
viral
protein
make
non
infecti
figur
vlp
abl
incorpor
peptid
vaccin
either
produc
recombin
genet
fuse
gene
encod
vlp
chemic
coupl
peptid
form
vlp
pejawargaddi
et
al
gener
bovin
papillomaviru
bpv
vlp
chemic
coupl
synthet
deriv
human
peptid
peptid
aberrantli
express
wide
rang
ductal
adenocarcinoma
intens
studi
candid
cancer
vaccin
antigen
vlp
subcutan
administ
transgen
mice
lead
robust
activ
bone
marrowderiv
dc
present
antigen
cell
addit
immun
human
transgen
mice
selfantigen
vlp
vaccin
induc
ctl
delay
growth
transplant
tumor
elicit
complet
tumor
reject
anim
studi
other
demonstr
vlp
could
effici
taken
apc
lead
mhc
class
ii
present
addit
vlp
abl
induc
potent
antiviru
humor
cellular
immun
respons
sever
vaccin
base
vlp
current
approv
human
use
gardasil
cervarix
demonstr
vlp
provid
appropri
immun
papillomaviru
moreov
vlpbase
vaccin
develop
includ
vaccin
influenza
hiv
norwalk
viru
clinic
trial
virosom
similar
viruslik
particl
consist
reconstitut
viral
envelop
lack
viral
genet
materi
gener
viru
deterg
solubil
reconstitut
procedur
main
differ
vlp
vlp
selfassembl
viral
capsid
protein
virosom
use
envelop
phospholipid
bilay
platform
addit
viral
compon
antigen
attach
figur
virosom
may
produc
varieti
envelop
virus
although
use
one
influenza
viru
fact
virosom
approv
vaccin
inflex
epax
compos
influenza
virosom
influenza
virosom
possess
membran
fusion
properti
similar
nativ
viru
maintain
receptorbind
membran
fusion
activ
viral
haemagglutinin
therefor
virosom
enter
cell
receptormedi
endocytosi
process
result
infect
cell
virosom
lack
viral
rna
foreign
macromolecul
includ
synthet
protein
antigen
encapsul
virosom
reconstitut
process
virosom
abl
induc
power
class
mhcrestrict
ctl
respons
mainli
deliv
content
cell
cytosol
favour
crosspresent
make
virosom
possibl
use
suitabl
deliveri
system
tumor
immunotherapi
hand
fraction
particl
inevit
degrad
within
endosomallysosom
compart
result
peptid
abl
associ
mhc
ii
molecul
result
respons
develop
antibodi
respons
found
upon
administr
malari
synthet
antigen
contain
virosom
fact
igg
antibodi
synthet
peptid
deriv
circumsporozoit
protein
p
faciparum
inhibit
invas
hepatocyt
p
falciparum
sporozoit
second
peptid
base
domain
iii
apic
membran
antigen
induc
antibodi
inhibit
bloodstag
parasit
growth
vitro
combin
antigen
differ
virosom
affect
neg
antipeptid
antibodi
titer
mice
rabbit
demonstr
valu
system
develop
multival
vaccin
addit
phase
clinic
trial
carri
order
evalu
safeti
immunogen
two
virosomeformul
p
falciparum
deriv
synthet
peptid
antigen
ama
vaccin
result
safe
seriou
sever
advers
event
observ
term
immunogen
formul
elicit
alreadi
antibodi
specif
respons
volunt
appropri
dose
immunostimulatori
complex
iscom
cagelik
structur
approxim
nm
diamet
compos
antigen
cholesterol
phospholipid
saponin
held
togeth
hydrophob
interact
typic
entrap
antigen
amphipath
commonli
use
saponin
quila
purifi
compound
iscomatrix
essenti
structur
iscom
lack
antigen
subsequ
ad
figur
fact
provid
iscomatix
gener
applic
limit
amphipath
antigen
although
numer
studi
carri
anim
model
clinic
trial
evalu
iscom
iscomatrix
current
cours
iscom
immunogen
although
saponin
differ
quila
use
antigen
incorpor
trigger
humor
mucos
cellular
immun
respons
differ
result
obtain
evalu
iscom
immunogen
instanc
agraw
et
al
administ
footpad
mice
differ
deriv
synthet
peptid
without
immunoadjuv
liposom
iscom
compar
administr
peptid
alum
contrast
alum
liposom
iscom
induc
predomin
like
respons
hand
pahar
et
al
found
intrarect
immun
macaqu
two
hivderiv
peptid
sivgag
incorpor
iscom
induc
low
level
immun
simianhiv
differ
may
due
antigen
use
differ
administr
rout
dose
schedul
iscomatrix
adjuv
facilit
antigen
deliveri
present
well
immunomodul
provid
enhanc
acceler
immun
respons
moreov
capabl
induc
broad
potent
humor
cellular
immun
respons
includ
cell
respons
antibodi
respons
often
achiev
lower
amount
antigen
adjuv
system
addit
iscomatrix
adjuv
use
vaccin
induct
mucos
immun
respons
fact
protect
abil
iscomatrix
adjuv
vaccin
report
use
veterinarian
vaccin
iscomatrix
adjuv
also
effect
field
cancer
treatment
protein
express
mani
cancer
recombin
protein
iscomatrix
adjuv
evalu
clinic
trial
demonstr
vaccin
safe
highli
immunogen
recent
ebert
et
al
studi
effect
peptid
synthet
deriv
tetram
iscomatrix
human
found
vaccin
formul
allow
dc
crosspres
epitop
effici
gener
potent
cell
respons
regard
safeti
concern
anderson
et
al
pool
analyz
safeti
data
obtain
number
vaccin
develop
program
compris
iscomatrix
overal
iscomatrix
vaccin
found
safe
well
toler
vaccinerel
death
seriou
advers
event
reactogen
inject
site
found
frequent
advers
event
compar
subject
receiv
placebo
activ
compar
howev
reactogen
gener
mild
selflimit
short
durat
end
studi
iscomatrix
vaccin
associ
event
suggest
autoimmun
allerg
disord
event
anaphylaxi
recent
cation
immun
stimul
complex
develop
pluscom
contrast
iscom
pluscom
abl
incorpor
hydrophil
peptid
adsorb
onto
surfac
ionic
interact
addit
effect
classic
iscom
induc
antigenspecif
cell
respons
use
nanobead
vaccin
carrieradjuv
system
impli
coupl
solid
inert
bead
gener
made
carboxyl
polystyren
antigen
bead
nm
better
intern
dc
higher
one
induc
type
immun
respons
wherea
larger
bead
facilit
respons
studi
carri
vivo
accord
find
particl
size
rang
could
elicit
antibodi
cell
immun
mice
well
provid
protect
tumor
challeng
later
find
also
confirm
sheep
instanc
administr
multipl
synthet
peptid
deriv
footandmouth
diseas
viru
conjug
separ
individu
nanobead
conjug
mixtur
abl
induc
signific
cellmedi
humor
immun
respons
sheep
administ
intraderm
shown
combin
adjuv
increas
immun
respons
reason
novel
vaccin
formul
compris
combin
adjuv
common
combin
adjuv
differ
action
mechan
use
vaccin
deliveri
system
contain
antigen
immun
potenti
adjuv
instanc
combin
plga
nanoparticl
coencapsul
poorli
immunogen
melanoma
antigen
tyrosinaserel
protein
along
tolllik
receptor
ligand
lipid
led
therapeut
antitumor
effect
melanoma
subcutan
administr
mice
although
contain
synthet
peptid
licens
vaccin
compris
mixtur
adjuv
gardasil
compos
vlp
alum
fendrix
compris
approv
human
use
europ
usa
cervarix
includ
vlp
vaccin
present
high
immunogen
safe
vaccin
deliveri
system
incorpor
ligand
order
specif
target
apc
receptor
shown
ligand
graft
enhanc
uptak
microparticl
immun
cell
brandhonneur
et
al
studi
uptak
differ
ligandgraft
plga
microspher
alveolar
macrophag
pig
ex
vivo
three
differ
ligand
use
wga
lectin
weat
germ
agglutinin
interact
lectin
receptor
rgd
arginineglycineaspart
contain
peptid
interact
integrin
carbohydr
moieti
interact
manos
receptor
much
higher
uptak
observ
mannos
wga
rgdgraft
microspher
mainli
specif
mechan
phagocytosi
ligand
graft
microspher
peptid
like
serum
albumin
uptak
significantli
differ
ungraft
microspher
due
nonspecif
mechan
uptak
given
lack
receptor
bsa
rad
macrophag
among
prr
ligand
tlr
ligand
wide
studi
tlr
activ
lead
upregul
costimulatori
molecul
surfac
apc
well
releas
cytokin
tnf
addit
ligand
abl
trigger
crosspresent
therefor
tlr
facilit
coordin
innat
adapt
immun
activ
b
cell
well
memori
respons
shown
antigen
tlr
ligand
gener
potent
immun
respons
coencapsul
particl
understood
take
account
endosom
organel
dc
express
tlr
addit
poss
machineri
process
captur
antigen
present
mhc
molecul
consequ
simultan
deliveri
antigen
tlrligand
cytosol
may
lead
better
dc
activ
subsequ
develop
immun
respons
exist
least
member
tlr
recogn
differ
microbi
compon
instanc
recogn
bacteri
lipoprotein
lipopeptid
cooper
bind
lp
recogn
doubl
strand
rna
attach
flagellin
recogn
singlestrand
viral
rna
synthet
imidazoquinolin
recogn
dna
rich
nonmethyl
cpg
cytosinephosphorothioateguanin
one
wide
use
immunopotenti
adjuv
interact
either
cpg
present
bacteri
viral
dna
synthet
cpg
oligodeoxynucleotid
cpg
odn
vaccin
liposom
contain
synthet
peptid
deriv
lymphocyt
choriomening
viru
lcmv
cpg
motif
intramuscular
rout
result
effici
induct
antivir
cell
respons
complet
protect
lcmv
also
highli
virul
mutant
strain
moreov
intranas
administr
induc
mucos
immun
abl
protect
mice
viru
challeng
even
use
low
dose
frequent
use
tlr
ligand
direct
poli
inosiniccytidil
acid
poli
c
synthet
analogu
doublestrand
rna
exert
function
via
poli
c
induc
matur
dc
potent
ifn
induc
activ
monocyt
nk
cell
produc
proinflammatori
cytokin
chemokin
furthermor
poli
c
abl
enhanc
specif
antitumor
immun
synthet
peptidebas
vaccin
induc
ctl
respons
mainli
allow
crossprim
shown
fluorescentbsaload
plga
microparticl
includ
poli
c
effect
phagocyt
dc
ex
vivo
induc
matur
similar
achiev
cytokin
cocktail
higher
concentr
solubl
poli
c
besid
murin
splenic
dc
puls
polyketalovapoli
c
microparticl
induc
higher
percentag
cell
dc
treat
polyketalova
particl
solubl
ovapoli
c
addit
target
tlr
deliveri
system
prepar
target
dc
receptor
carrier
incorpor
antibodi
molecul
specif
interact
receptor
dcsign
abil
trigger
phagocytosi
entrap
synthet
peptid
dc
promot
matur
vaccin
subunit
vaccin
compris
synthet
protein
peptid
alway
success
degrad
proteas
possess
limit
bioavail
present
rel
low
immunogen
deliveri
system
abl
overcom
problem
sinc
protect
protein
degrad
increas
bioavail
allow
cross
biolog
membran
regard
immun
respons
deliveri
system
improv
andor
modul
respons
achiev
solubl
peptid
alon
although
propos
exert
adjuvanc
gener
depot
effect
inject
site
current
action
mechan
found
better
explain
modul
improv
immun
respons
carrier
passiv
direct
subsequ
endocyt
apc
deliv
antigen
cytosol
intracellular
organel
addit
interact
protein
complex
inflammasom
activ
immun
respons
furthermor
incorpor
immunostimulatori
molecul
may
improv
modul
immun
respons
order
develop
humor
also
cellular
immun
deliveri
system
also
possess
advantag
safe
stabl
reproduc
besid
administ
sever
rout
offer
possibl
develop
mucos
system
immun
respons
featur
led
approv
system
clinic
use
vlp
virosom
tradit
alum
although
adjuv
abl
trigger
appropri
immun
respons
certain
pathogen
futur
field
focus
develop
combin
vaccin
better
design
induct
appropri
immun
respons
